This recruitment brings strategic capabilities to drive the development of Osivax’s lead candidate, a breakthrough influenza vaccine
Lyon, France – January 24th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Dr. Delphine Guyon-Gellin as Chief Business Development Officer.
“We are delighted to welcome Delphine Guyon-Gellin in our leadership team. Delphine’s extensive experience working with leading pharmaceutical companies, along with her in-depth expertise on strategy in vaccines, will be pivotal for Osivax as we enter the clinical phase for our lead influenza vaccine candidate”, said Alexandre Le Vert, CEO and cofounder of Osivax. “Her arrival will strengthen our capacities to better interact and build partnerships with the influenza community at large”.
Delphine Guyon-Gellin will be responsible for Corporate Development and Strategy at Osivax. As a Doctor of Veterinary Medicine with a strong experience in strategic consulting, she brings to Osivax her valuable global experience in solving strategic questions in Healthcare. Before joining Osivax, she worked for seven years at the Boston Consulting Group in Paris and then London and was involved in various strategic assignments in Healthcare, including many projects in Vaccines. Prior to this she worked for AEC Partners a strategic consulting firm specialised in Healthcare. Delphine graduated from National Veterinary School of Maisons-Alfort and holds a Master degree from HEC.
“As the holy grail in influenza prevention is to develop a universal flu vaccine, Osivax has a disruptive technology platform to induce powerful immune response against highly conserved influenza antigens” added Delphine Guyon-Gellin “As such, Osivax is well-positioned to make its mark and develop the next generation of influenza vaccines, and I look forward to joining the team at this pivotal time. Beyond influenza, Osivax’ technology platform is highly promising to address other severe unmet needs in oncology and infectious diseases.”
About Osivax
Osivax’s mission is to revolutionize influenza prevention with a universal flu vaccine for both current and future Influenza A and B infections by leveraging its unique oligoDOM® technology platform. The most advanced candidate, a broad-spectrum A-strain flu vaccine is in Phase 1 clinical development. Osivax is focused on providing proof-of-concept in Influenza A firstly to save lives and secondly to lay the groundwork for a universal flu vaccine as well as apply the platform to other infectious and immune system-associated diseases. For further information: www.osivax.com